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Who Receives Outpatient Monitoring During High-Risk
Depression Treatment Periods?
Helen C. Kales, MD,w H. Myra Kim, ScD, z Karen L. Austin, MPH, and
Marcia Valenstein, MD, MSw
OBJECTIVES: To examine the intensity of monitoring re-
ceived by important patient subgroups during high-risk pe-
riods (the 12 weeks after psychiatric hospitalization and
after new antidepressant starts).
DESIGN: Retrospective secondary analysis of data from
the Veterans Affairs (VA) National Registry for Depression
using patients aged 65 and older receiving depression treat-
ment from 1999 to 2004.
SETTING: VA healthcare system.
PARTICIPANTS: VA patients in depression treatment be-
tween April 1, 1999, and September 30, 2004, who had
psychiatric inpatient stays (n 5 73,137) or new antidepres-
sant starts (n 5 421,536).
MEASUREMENTS: The relationship between the number
of outpatient visits for each group and patient character-
istics in the 12-week period after psychiatric hospitaliza-
tions and antidepressant starts.
RESULTS: The characteristic associated with significantly
lower rates of monitoring for both high-risk treatment pe-
riods was aged 65 and older. White race and living in the
south or northeast were also associated with significantly
lower rates of monitoring after new antidepressant starts
and inpatient stays, respectively. Substance abuse disorders
were associated with greater monitoring after both types of
depression events but did not seem to interact with other
patient characteristics in determining levels of monitoring.
CONCLUSION: VA patients who are older, white, and
living in the south or northeast receive less-intensive mon-
itoring during high-risk treatment periods for suicide. This
is of concern, given that older patients appear to be at
higher risk for suicide, particularly after inpatient stays, and
may need particular attention during this time frame.
Adapted interventions and proactive outreach may be
needed that target this patient group. J Am Geriatr Soc
58:908–913, 2010.
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In 2003, the Food and Drug Administration (FDA)warned clinicians that antidepressants might increase
suicidality in children and adolescents and recommended
close monitoring of patients newly started on these med-
ications for symptoms of suicidal ideation. Although not
proven to reduce suicides, the close monitoring of patients
during high-risk periods is considered an important element
of many clinical prevention efforts.1 Guidelines vary tre-
mendously in terms of recommendations for frequency and
timing of follow-up visits for patients beginning antide-
pressants. The National Committee for Quality Assurance
(NCQA) developed the most commonly used set of mea-
sures for improving depression treatment efficacy. In the
NCQA Health Employer Data and Information Set (HE-
DIS), ‘‘optimal provider contact’’ is defined as a minimum
of three follow-up visits for mental health care in the 12
weeks after a new antidepressant start.2,3 The FDA has
made a number of monitoring recommendations for peri-
ods after antidepressant starts, with the most stringent rec-
ommendation being seven visits in 12 weeks for children
and adolescents.4 One FDA advisory suggested that adults
should be monitored similarly.5
Prior studies have consistently documented far less
monitoring than the FDA or NCQA recommendations. A
2006 study noted that only 23% of patients received the
FDA-recommended level of care at 12 weeks.2 Another
study6 found that the visit frequency of patients with new
episodes of depression treated with antidepressants did not
change after the 2003 FDA advisory, with only approxi-
mately 40% of adults meeting HEDIS criteria at 12 weeks.
With limited resources, health systems may need
to prioritize the ‘‘when’’ and the ‘‘who’’ of clinical moni-
toring efforts. In terms of the ‘‘when,’’ research and clinical
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monitoring efforts have typically focused on the 12-week
period after new antidepressant starts, but given finite re-
sources, there are few data on which treatment periods
should be considered highest risk and therefore prioritized
for prevention efforts. A prior study established that Vet-
erans Affairs (VA) patients in depression treatment have
higher suicide rates during two readily identifiable treat-
ment periods: the 12 weeks after psychiatric hospitalization
and new antidepressant starts.7 Risks were highest after
inpatient hospitalization, with suicide rates greater than
568 per 100,000 person-years (approximately five times the
overall base rate). After new antidepressant starts, suicide
rates were 210 per 100,000 person-years. Smaller eleva-
tions in the suicide rate were found in the 12-week periods
after other antidepressant starts (e.g., switches) or dose
changes.
There is even more-limited information on ‘‘who’’
should or does receive the closest monitoring. Prior studies
have noted that certain patient populations may be at
higher risk for inadequate depression care (e.g., antidepres-
sant dosage and duration adequacy), including younger age,
African-American race, and exclusive primary care treat-
ment.8 In a prior study,5 older patients had the same pat-
terns in terms of periods of risk as in the overall sample. In
addition, in other analyses performed in that study, older
patients had significantly higher absolute rates than young-
er patients in the periods after psychiatric hospitalization;
here, veterans aged 61 to 70 had a suicide rate per 100,000
person-years of 1,234.8, versus a rate of 673.5 for veterans
30 or under. However, to the authors’ knowledge, there are
few data on which patient subgroups receive more-intensive
monitoring during high-risk periods for suicide. Given the
advisability of close outpatient monitoring during these
high-risk periods, whether certain patient characteristics
(age, race, sex, marital status, living region, and comorbid-
ities) were associated with disparities in monitoring was
examined. A unique longitudinal VA data set with compre-
hensive diagnosis, utilization, and pharmacy data was used
to examine rates of clinical monitoring during the two
highest-risk treatment periods (12 weeks after inpatient stay
and after new antidepressant start) in a comprehensive
sample of VA patients in depression treatment between
April 1, 1999, and September 30, 2004.
METHODS
Data for this study were obtained from the VA’s National
Registry for Depression (VARDEP), which was developed
by the VA’s Serious Mental Illness Treatment Research and
Evaluation Center (SMITREC) in Ann Arbor, Michigan.
The institutional review board of the VA Ann Arbor Health
System approved this study.
Study Population
The study population consisted of patients in the National
Registry for Depression between April 1, 1999, and Sep-
tember 30, 2004. Entry into the study required two de-
pression diagnoses or a diagnosis of depression and an
antidepressant fill. Depression diagnoses were identified
using International Classification of Diseases, Ninth Revi-
sion (ICD-9) codes 296.2x, 296.3x, 296.90, 296.99, 298.0,
300.4, 311, 293.83, 301.12, 309.0, and 309.1. Patients
with diagnoses of bipolar I or II, schizophrenia, or schizo-
affective disorder during the study period were excluded.
Patients were also excluded if they had unknown or missing
race, were younger than 18, or had a missing value for
region.
Treatment Events and High-Risk Cohorts
Because monitoring may be inherently different during the
high-risk period after a psychiatric hospitalization than it is
after a new antidepressant start, two separate cohorts were
constructed based on the presence of these treatment events.
The inpatient cohort comprised patients who had a psy-
chiatric inpatient hospitalization, and observation days
started from the discharge date. The new-start cohort com-
prised patients who had a new antidepressant start.
Psychiatric hospitalizations were defined as hospital-
izations with a primary psychiatric discharge diagnosis of
ICD-9 codes 290.x to 319.x or hospitalizations with bed
section codes of 33, 38, 39, 70 to 74, 79, 84, or 89 to 94. A
new antidepressant start was defined as an antidepressant
medication fill within the VA system that occurred after a
‘‘clean period’’ of 6 months or longer without any antide-
pressant fills. As in prior studies, trazodone, mirtazapine,
amitriptyline, and nortriptyline were considered to have
been used as antidepressants rather than for other purposes
only if the doses were 300, 15, 75, or 25 mg per day or
greater, respectively.9
Observation Days for the 84-Day High-Risk Periods
Observation days for study analyses began on the date of
patients’ first new antidepressant treatment for the
new-start cohort and on the day of discharge from the first
psychiatric hospitalization for the inpatient cohort and
continued for the next 84 days. Patients were excluded
(36,928 patients from the new-start cohort and 21,268
from the inpatient cohort) if they had fewer than 84 days
(12 weeks) of observation after the treatment event because
of death (as indicated in the National Death Index) or the
end of the study period (September 30, 2004). For each
patient, only the first qualifying treatment event followed
by at least 84 high-risk days was considered. Any nonpsy-
chiatric or psychiatric inpatient hospitalization days that
occurred during the high-risk period of 84 days were ex-
cluded from the number of high-risk days because only
outpatient monitoring visits were of interest. Also, any days
after a psychiatric hospitalization that occurred during the
high-risk period were excluded from the number of high-
risk days because postpsychiatric hospitalization days
would indicate potential changes in risks. This meant that
there were fewer than 84 high-risk days for those with any
hospitalization within the 84 days after the index new an-
tidepressant start for the new-start cohort or after the initial
discharge date for the inpatient cohort.
Monitoring
Monitoring visits were defined using the VA-modified HE-
DIS criteria. A HEDIS visit is an outpatient visit that has a
psychiatric Current Procedural Terminology (CPT) code or
visits that have a mental health diagnosis with a nonpsy-
chiatric CPT code. All monitoring visits occurring during
high-risk days (the 12 weeks after an inpatient hospitaliza-
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tion or new antidepressant start) were identified. Only one
monitoring visit was counted on any given day, even if more
than one visit was made.
Patient Characteristics
Patients were categorized into three age groups (18–44, 45–
64, and 65) based on their age at the beginning of cohort
entry. Each patient was classified into one of three racial
categories (African American, white, or other), and pa-
tients’ ethnicity was defined as Hispanic or non-Hispanic.
Having a psychiatric comorbidity was defined as having at
least one diagnosis of posttraumatic stress disorder, per-
sonality disorder, or anxiety disorder during the period
from 12 months before cohort entry through the end of the
study period. Similarly, a substance abuse comorbidity was
defined as having at least one diagnosis of alcohol or other
substance use in the same time frame. Having a medical
comorbidity was defined as having at least one of the 20
Charlson medical comorbidities10 during the 12 months
before cohort entry.
Data Analyses
Descriptive statistics were computed for patient character-
istics, using frequencies or means as appropriate. Analyses
examining the relationships between the rate of monitoring
during high-risk treatment periods and patient characteris-
tics were completed separately for the two cohorts. Distri-
bution of the number of visits during high-risk periods was
examined graphically, and the rate of monitoring per 84
high-risk days was calculated as 84  (total number of vis-
its/total high-risk days) and reported as a summary mea-
sure. To assess the relationship between level of monitoring
and patient characteristics, multiple regression models and
negative binomial models were used. Negative binomial
models were needed because the distribution of number of
visits was skewed, with the majority of patients having just 0,
1, or 2 visits during high-risk periods but with some patients
having many more visits. In the model, total number of visits
was capped at 20 (i.e., patients with 420 visits were cat-
egorized as having 20 visits). The model also allowed
adjustment for the total number of high-risk days, which was
less than 84 days for those with a hospitalization within the
84 days after discharge from the index psychiatric hospital-
ization or after the new antidepressant start. The coefficients
from a negative binomial model were exponentiated to re-
flect relative risks. For example, a coefficient of 0.5 for
women would correspond to an increase in monitoring visits
of about 65% (5 exp(0.5)) in women relative to men when
other variables were held constant. All analyses were per-
formed using SAS version 9.2 (SAS Institute, Inc., Cary, NC).
In either cohort, patients who had at least one subse-
quent hospitalization during the 84-day high-risk period
after entry into the cohort may have been monitored more
intensively even before the hospitalization. In addition, a
varying number of high-risk days across patients might bias
the estimation of the strength of the relationship even with
the use of a model adjusting for exposure. Therefore, the
analyses were repeated after excluding patients who had
one or more hospitalizations within the high-risk period to
see if the results in the subsample with the full 84 high-risk
days differed from those of the main analyses.
Analyses were also performed after stratifying accord-
ing to substance abuse status and each of the three age
groups (18–44, 45–64, and 65) and using location of in-
dex antidepressant start (primary care vs mental health).
The latter was determined based upon the clinic visit that
directly preceded the antidepressant fill.
RESULTS
Patient Sample
The characteristics of patients undergoing VA depression
treatment during the study period (N 5 798,217) are outlined
in Table 1. The study sample comprised patients who had
psychiatric inpatient stays (n 5 73,137) or new antidepressant
starts (n 5 421,536). These groups had a mean age  stan-
dard deviation of 52.2  12.6 for the inpatient cohort and













Female 59,080 (7.4) 3,831 (5.2) 33,155 (7.9)
Male 739,137 (92.6) 69,306 (94.8) 388,381 (92.1)
Race
African American 108,612 (13.6) 18,178 (24.9) 55,614 (13.2)
White 671,008 (84.1) 53,094 (72.6) 356,031 (84.5)
Other 18,597 (2.3) 1,865 (2.6) 9,891 (2.4)
Hispanic
No 759,663 (95.2) 69,393 (94.9) 399,815 (94.9)
Yes 38,554 (4.8) 3,744 (5.1) 21,721 (5.2)
Age
18–44 114,073 (14.3) 19,161 (26.2) 63,093 (15.0)
45–64 387,218 (48.5) 42,960 (58.7) 199,515 (47.3)
65 296,926 (37.2) 11,016 (15.1) 158,928 (37.7)
Marital status
Married 437,768 (54.8) 25,999 (35.5) 233,945 (55.5)
Not married 356,885 (44.7) 47,025 (64.3) 185,801 (44.1)
Any substance abuse
No 620,569 (77.7) 24,841 (34.0) 335,435 (79.6)
Yes 177,648 (22.3) 48,296 (66.0) 86,101 (20.4)
Comorbid psychiatric diagnosisw
No 451,906 (56.6) 29,923 (40.9) 249,046 (59.1)
Yes 346,312 (43.4) 43,214 (59.1) 172,490 (40.9)
Charlson medical comorbidity
0 476,676 (59.7) 47,468 (64.9) 268,731 (63.8)
1 321,541 (40.3) 25,669 (35.1) 152,805 (36.3)
Region (location on entry into cohort)
Northeast 161,781 (20.3) 15,793 (21.6) 81,768 (19.4)
Central 179,746 (22.5) 17,852 (24.4) 94,601 (22.4)
South 302,843 (37.9) 25,257 (34.5) 164,382 (39.0)
West 153,847 (19.3) 14,235 (19.5) 80,785 (19.2)
Diagnosis of alcohol or other substance abuse 12 months before entry
through end of study period.
wDiagnosis of posttraumatic stress disorder, personality disorder, or other
anxiety disorder 12 months before entry through end of study period.
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59.6  14.4 for the new-start cohort and were predominantly
male (95% and 92%, respectively). A higher percentage of
inpatients were African American, younger, and unmarried
and had substance abuse and psychiatric comorbidity.
Monitoring After Psychiatric Inpatient Stays
The number of visits after a psychiatric inpatient stay was
highly skewed. Approximately 4% of patients had more than
20 visits during the high-risk period, although the median
number of visits during this 84-day period was 2. The mean
visit rate during the high-risk period was 4.56 visits (95%
confidence interval (CI) 5 4.55–4.58), a rate that differed
significantly according to patient characteristics (Table 2).
The patient characteristic associated with significantly
lower rates of monitoring for the postinpatient period was
aged 65 and older (relative risk (RR) 5 0.71, 95%
CI 5 0.69–0.74, relative to o45). Substance abuse disor-
ders (RR 5 1.49, 95% CI 5 1.45–1.52) and having a psy-
chiatric comorbidity (RR 5 1.57, 95% CI 5 1.54–1.61)
were associated with higher monitoring rates after psychi-
atric hospitalizations. Monitoring visits varied greatly ac-
cording to region, with those living in the south (RR 5 0.77,
95% CI 5 0.75–0.79) and northeast (RR 5 0.80, 95%
CI 5 0.78–0.82) being monitored significantly less than
those in the midwest (reference) region.
Monitoring After New Antidepressant Starts
The number of visits after new antidepressant starts was
also highly skewed, with 0.46% having at least 20 visits,
although the median number of visits was 1. The mean
monitoring visit rate was 2.03 per 84 days (95% CI 5 2.02–
2.04) in the new-start cohort. Examining the new-start
cohort, it was found that 23.9% of patients met the sug-
gested NCQA recommendations for three or more visits
during the 84-day period. Only 4.7% of patients met the
FDA monitoring recommendation of seven or more visits.
Characteristics associated with significantly lower rates of
monitoring included aged 65 and older (RR 5 0.75, 95%
CI 5 0.74–0.76) and white race (RR 5 0.83, 95%
CI 5 0.82–0.84). Substance abuse disorders (RR 5 1.53,
95% CI 5 1.52–1.55) and having a psychiatric comorbidity
(RR 5 1.55, 95% CI 5 1.54–1.56) were associated with
higher rates of monitoring. Unlike in the inpatient cohort,
monitoring did not vary significantly according to region.
Sensitivity Analyses
When the analyses were repeated after excluding those who
had at least one subsequent hospitalization within the 84-
day high-risk period, the relationships between patient
characteristics and rate of monitoring remained nearly
identical to those in the main analyses. A surprisingly large
percent, i.e., 20.5% (n 5 15,008), of the inpatient cohort
had a subsequent rehospitalization during the high-risk pe-
riod, whereas only 4.4% (n 5 18,383) of new-start cohort
had a hospitalization during the high-risk period.
To explore whether some of the monitoring patterns
seen with regard to sex and race differed with age and sub-
stance abuse comorbidities, analyses were also done after
stratifying according to substance abuse status and each of
the three age groups (18–44, 45–64, and 65). In these
analyses, characteristics associated with lower rates of
monitoring were similar to the overall analyses.
Table 2. Results from Negative Binomial Regression Models
Variable
RR (95% Confidence Interval)w
Inpatient Cohort New-Start Cohort
All Patients Full 84 Days All Patients Full 84 Days
n 5 73,137 n 5 58,129 n 5 421,536 n 5 403,153
Age (reference o45)
45–64 1.08 (1.05–1.10) 1.12 (1.09–1.15) 0.95 (0.94–0.95) 0.95 (0.95–0.96)
65 0.71 (0.69–0.74) 0.75 (0.72–0.78) 0.75 (0.74–0.76) 0.75 (0.74–0.76)
Race (reference African American)
White 0.93 (0.90–0.95) 0.92 (0.90–0.94) 0.83 (0.82–0.84) 0.84 (0.83–0.84)
Other 0.91 (0.85–0.97) 0.94 (0.88–1.01) 0.94 (0.92–0.95) 0.95 (0.93–0.97)
Hispanic 1.08, (1.03–1.13) 1.09 (1.04–1.14) 1.08 (1.07–1.10) 1.08 (1.07–1.10)
Female 1.13 (1.08–1.19) 1.17 (1.12–1.23) 1.00 (0.99–1.01) 1.01 (1.00–1.02)
Comorbid psychiatric diagnosis 1.57 (1.54–1.61) 1.57 (1.54–1.61) 1.55 (1.54–1.56) 1.55 (1.54–1.56)
Comorbid substance abuse 1.49 (1.45–1.52) 1.41 (1.37–1.44) 1.53 (1.52–1.55) 1.48 (1.47–1.49)
Medical comorbidity 0.91 (0.89–0.93) 0.91 (0.88–0.93) 0.97 (0.97–0.98) 0.96 (0.96–0.97)
Married 1.02 (1.00–1.04) 1.08 (1.05–1.11) 0.92 (0.91–0.92) 0.92 (0.92–0.93)
Region (reference midwest)
South 0.77 (0.75–0.79) 0.78 (0.76–0.80) 0.88 (0.87–0.89) 0.89 (0.88–0.89)
Northeast 0.80 (0.78–0.82) 0.83 (0.81–0.86) 1.02 (1.01–1.03) 1.03 (1.02–1.04)
West 0.85 (0.83–0.88) 0.88 (0.85–0.91) 1.11 (1.10–1.12) 1.12 (1.11–1.13)
 Includes those with no subsequent hospitalizations within the 84-day high-risk period.
wRelative risk (RR) refers to the likelihood of receiving outpatient follow-up; a RR of o1 indicates that a particular group was less likely to receive follow-up
than the reference group.
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Analyses were also performed using location of the in-
dex antidepressant start (mental health (MH); primary care
(PC)), controlling for covariates, including substance abuse
and psychiatric comorbidity, as well as demographic char-
acteristics. Here it was found that, overall, MH patients
were more likely to be monitored than PC patients in all
three age groups, with a RR of MH versus PC of 1.68
(Po.001) for younger than 45, 1.88 (Po.001) for age 45 to
64, and 1.74 (Po.001) for aged 65 and older. It was also
found that the age effects for older patients seen in the main
analyses held regardless of location of the index visit. Spe-
cifically, older (65) patients were less likely to be moni-
tored than younger (o45) patients (RR 5 0.86, Po.001,
when index start was in PC, RR 5 0.90, Po.001, when
index start was in MH).
DISCUSSION
A unique longitudinal VA data set with comprehensive di-
agnosis, utilization, and pharmacy data was used to exam-
ine rates of clinical monitoring during the two highest-risk
treatment periods (12 weeks after inpatient stay and after
new antidepressant start) in a comprehensive sample of VA
patients in depression treatment. Characteristics associated
with significantly lower rates of monitoring included
older age, white race, and living in the south or northeast.
Older age has been associated with higher risks of suicide
after psychiatric hospitalization.5
The results indicating significantly less depression mon-
itoring for older patients are troubling but perhaps not sur-
prising. In terms of new antidepressant starts, most older
adults with depression are identified by their primary care
physicians and treated as part of their overall medical
care.11 Multiple prior studies in the 1990s indicated that
depression was underdiagnosed and undertreated in older
adults.12–14 Although there is ample evidence that antide-
pressant therapy can effectively ameliorate symptoms of
later-life depression,15–17 a number of factors or confounds
create complexity in its overall management.18 Patient fac-
tors, such as medical illness and neuropsychiatric comor-
bidity, may interact with provider factors to make
treatment more complex. Even in the inpatient cohort in
this study, most of whom would be expected to have psy-
chiatric outpatient follow-up after hospitalization, the rates
of monitoring were significantly lower than in younger
adult patients. Factors such as comorbidity and functional
impairment, as well as provider scheduling decisions, pa-
tient preferences, and transportation problems, may have
played a role in preventing older patients from returning to
the clinic as often as their younger counterparts.
Although the FDA meta-analysis did not show greater
risks when older adults were randomized to an antidepres-
sant rather than a placebo, the monitoring recommendation
did not appear to be amended for older adults (i.e., the FDA
made no new recommendation regarding a lower visit fre-
quency for this population). However, providers may have
noted the FDA meta-analysis results and not felt as much
need to follow older adults as closely. This would perhaps
stem from concern over the risks of suicide ensuing from
depression medication itself rather than absolute suicide
rates. Prior work5 showed that, in clinical settings, these
periods are very high risk for older adults, probably because
of the illness severity that prompted the medication initi-
ation or change rather than a medication effect per se.
During the period of this study, the VA had mandated
annual depression screening. In its depression guidelines, it
recommended regular follow-up for new depression epi-
sodes. It also emphasized following HEDIS guidelines for
follow-up after psychiatric hospitalization and document-
ing outpatient visits in the first 7 days after discharge and in
the first month after discharge. Aside from mandated an-
nual screening, the guideline recommendations and follow-
up recommendations were similar to those that other health
systems use, although they may have been more rigorously
monitored and emphasized in the VA. More recently (after
this study period), the work outlined in a prior study5 was
widely disseminated in VA settings. Subsequently, more-
intensive monitoring has been implemented for post-
hospitalization periods, probably in part because of the
documentation of high suicide risks during this period.
Given these results demonstrating that older adults re-
ceive less-intensive monitoring during high-risk periods,
these patients may require adapted interventions to obtain
the follow-up for depression care that they require. The VA
has recently initiated home-based primary care programs
for medically ill and older veterans. Routinely including
depression care as part of these programs could enhance
monitoring efforts for patients who may find it difficult to
return to the clinic for more-frequent outpatient visits.
Health systems serving large numbers of older patients may
need to consider guidelines and follow-up measures specific
to older adults during high-risk treatment periods.
Somewhat less expected were the results for African-
American patients indicating that they had significantly
more monitoring visits than white patients after new anti-
depressant starts. These findings could not be explained by
increased care due to substance use comorbidities in the
exploratory analyses stratified by substance abuse diag-
nosis. Prior studies have shown that minorities have sig-
nificantly lower rates of mood disorder diagnoses,19 may be
less likely to receive guideline-concordant antidepressant
treatment20 or to fill prescriptions for antidepressant med-
ications than whites,21 and may prefer counseling to med-
ications.22 However, the results of the present study are
similar to an earlier analysis in which no racial differences
were found in healthcare usage for mood disorders in older
patients diagnosed with depression in the VA system.23 Ad-
ditionally, other studies have found that African Americans
are more likely than whites to receive an adequate course of
psychotherapy in VA24 settings. The findings of the current
study support the idea that the VA may be doing a good job
reaching out to racial minority patient groups who have
been traditionally underserved with depression care.
Limitations
This article reports significantly lower monitoring rates for
older than younger patients during high-risk treatment pe-
riods (after antidepressant starts and hospitalization);
higher suicide rates have previously been reported in older
than younger patients in this cohort during the posthospital
period. However, in this article, the observational data were
not used to directly assess the relationship between lower
rates of monitoring and suicide risks in older adults. To do
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so would require highly complex analyses, given the small
number of completed suicides (suicide is a low base rate
event) and salient issues of treatment selection in clinical
settings. In clinical settings, treatments are not assigned at
random, and patients with more-severe mental health prob-
lems often have more-frequent visits and are more likely to
commit suicide, resulting in potentially spurious associa-
tions between high monitoring rates and suicide. Thus, even
though the mental health literature, governmental organi-
zations, and clinical practice guidelines routinely suggest
higher levels of monitoring for higher risk populations, it
may be that greater monitoring would not result in reduc-
tion in suicide risks in older patients.
The study has a number of other limitations. Consistent
with the demographic characteristics of the VA patient
population, the study cohort was primarily male, and thus
the results may not be generalizable to other clinical pop-
ulations. Additionally, antidepressant fills and hospitaliza-
tions within the VA were relied upon to characterize
high-risk periods. Some patients may have used mental
health services outside of the VA system, although prior
reports indicate that only a minority of VA mental health
users receive care in other health systems.25,26 Older adults,
in particular, may often exclusively use the VA because of
generous drug benefits. It is also possible, given the VA’s
monitoring efforts, that depressed older patients during the
time of the study may have been followed somewhat more
closely in the VA than in other settings.
CONCLUSIONS
Characteristics associated with significantly lower rates of
monitoring in two different high-risk periods for patients in
depression treatment include older age, white race, and liv-
ing in the south or northeast. Older adults may be more in
jeopardy for inadequate monitoring during high-risk peri-
ods; these patients may require adapted interventions to
obtain the depression care follow-up that they require.
Health systems serving large numbers of elderly patients
may need to consider additional guidelines and follow-up
measures specific to older adults during high-risk treatment
periods. In addition, further studies are needed to better
understand why follow-up rates, particularly after hospi-
talization, are lower for older adults.
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